The average survival rate for patients with myelofibrosis is six years. But this varies based on potential treatments. There are no drugs that can modify the outcome for myelofibrosis, and the only treatment that leads to cure is an allogeneic hematopoietic cell transplantation (allo-HCT). However, because of the high rates of morbidity and mortality, this treatment must be carefully considered based on the patient. CANCER BUZZ spoke to Gabriela S. Hobbs. MD, Assistant Professor of Medicine, Harvard Medical School, and Clinical Director of Leukemia, Massachusetts General Hospital in Boston, MA. Listen as Dr. Hobbs discusses symptom scoring, risk stratification, and effective practices in building a strong myelofibrosis program.
“…If a patient is higher risk, they should be referred to transplant; also patients who are high risk are more likely to have low blood counts, low platelets, and low red blood cells that may also influence how these patients are treated.” – Gabriela S. Hobbs. MD
This project is supported by AbbVie and GSK.
Gabriela S. Hobbs. MD
Assistant Professor of Medicine
Harvard Medical School
Clinical Director of Leukemia
Massachusetts General Hospital
Boston, MA
Resources:
Leukemia & Lymphoma Society
MPN Research Foundation
Social Determinants of Health in Metastatic Breast Cancer
Overcoming Barriers to Holistic Survivorship Care for Immunotherapy Patients
Integrating Genetic Counselors in Routine Genitourinary Care
A Multidisciplinary Approach to Anemia Management in High-Risk MDS and AML
Improving Care Delivery to Patients Newly Diagnosed with Breast Cancer
Highlights from the ACCC Working Summit: Advancing CAR T-Cell Therapy Care Continuity and Collaborative Patient Education
Care Action Plans for People with Cancer
Beyond the Brush: Navigating Dental Care in Head & Neck Cancer
Navigating the Operational Challenges of Treatment with Bispecific Antibodies
Policy Perspectives on Biomarker Testing Coverage for 2024
Open Enrollment: Best Practices for End-of-Year Prep
Disparities in Accessing Care for AML Patients: Challenges and Solutions
Clarifying the Role of Maintenance Therapy
A Conversation With ACCC’s Outgoing and Incoming Presidents at the ACCC 50th Annual Meeting and Cancer Center Business Summit
LIVE from AMCCBS: White House Update
LIVE from AMCCBS: Capitol Hill Update
LIVE from AMCCBS: Institute for Comprehensive Cancer Care Services
LIVE from AMCCBS: New Payments for Patient Navigation
LIVE from AMCCBS: Financial Advocacy Resources
Making the Case for Head & Neck Cancer Patient Care Navigators
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain